# Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects

> **NCT03627767** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 1235 (actual)

## Conditions studied

- Dermatitis
- Dermatitis, Atopic
- Eczema
- Skin Diseases
- Skin Diseases, Genetic
- Genetic Diseases, Inborn
- Skin Diseases, Eczematous
- Hypersensitivity
- Hypersensitivity, Immediate
- Immune System Diseases

## Interventions

- **DRUG:** PF-04965842 100 mg
- **DRUG:** PF-04965842 200 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03627767
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-11
- **Primary completion:** 2020-09-02
- **Final completion:** 2020-10-07
- **Target enrollment:** 1235 (ACTUAL)
- **Last updated:** 2021-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03627767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03627767, "Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03627767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*